{{redirect|Chymex|the human body digestive fluid|Chyme}}
{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 459858799
| ImageFile=Bentiromide.svg
| ImageSize=150px
| IUPACName=<small>4-[2-benzamido-3- (4-hydroxyphenyl)- propanoyl] aminobenzoic acid</small>
| OtherNames=<small>(S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl) -1-oxopropyl)amino)benzoic acid<br />(S)-p-(α-benzamido-p-hydroxyhydrocinnamamido) benzoic acid<br />Benzoyltyrosyl-p-aminobenzoic acid (Btpaba)Chymex<br />N-benzoyl-L-tyrosyl-p-aminobenzoic acid<br />P-((N-benzoyl-L-tyrosin)amido)benzoic acid<br />Chymex (trade name)</small>
| Reference=<ref>[https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2329&loc=ec_rcs Bentiromide – Compound Summary], [[PubChem]].</ref>
|Section1={{Chembox Identifiers
| EINECS=253-349-8
| PubChem = 6957673
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200368
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID=5329364
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank= DB00522
| Abbreviations=Btpaba
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 239IF5W61J
| InChIKey = SPPTWHFVYKCNNK-FQEVSTJZBR
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)/t20-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SPPTWHFVYKCNNK-FQEVSTJZSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo=37106-97-1
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 31263
| SMILES = O=C(O)c1ccc(cc1)NC(=O)[C@@H](NC(=O)c2ccccc2)Cc3ccc(O)cc3
| InChI = 1/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)/t20-/m0/s1
}}
|Section2={{Chembox Properties
| Formula=C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub>
| MolarMass=404.4153 g/mol
| Density=
| Solubility=
| SolubleOther=
| Solvent=
| MeltingPt=
| BoilingPt=
| pKa=
| pKb=
| IsoelectricPt=
| SpecRotation=
| RefractIndex=
| Viscosity=
| Dipole=}}
|Section3={{Chembox Structure
| CrystalStruct=
| Coordination=
| MolShape=
| Dipole=}}
|Section5={{Chembox Thermochemistry
| DeltaHf=
| DeltaHc=
| Entropy=
| HeatCapacity=}}
|Section6={{Chembox Pharmacology
| Bioavail=
| Metabolism=
| HalfLife=
| Excretion=
| Pregnancy_category =
| AdminRoutes=
| ATCCode_prefix = V04
| ATCCode_suffix = CK03
 }}
|Section4={{Chembox Explosive
| ShockSens=
| FrictionSens=
| DetonationV = 
| REFactor=}}
|Section7={{Chembox Hazards
| EUClass=
| MainHazards=
| NFPA-H=
| NFPA-F=
| NFPA-R=
| NFPA-S =
| RPhrases=
| SPhrases=
| RSPhrases=
| FlashPt=
| AutoignitionPt =
| ExploLimits =
| PEL=
}}
|Section8={{Chembox Related
| OtherAnions=
| OtherCations=
| OtherFunction =
| OtherFunction_label =
| OtherCompounds =}}
}}

'''Bentiromide''' is a [[peptide]] used as a screening test for [[exocrine]] [[pancreatic]] insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of [[p-aminobenzoic acid|4-aminobenzoic acid]] and its [[metabolites]] excreted in the urine is taken as a measure of the [[chymotrypsin]]-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the United States or Canada (it was withdrawn in the U.S. in October 1996.)

== Data ==
*XLogP=3.201
*tautomers=12
*H_bond_donor=4
*H_bond_acceptor=5
== Synthesis ==
Synthetic chymotrypsin-labile peptide, used in diagnosis of exocrine pancreatic disease.
[[File:Bentiromide synthesis.svg|thumb|center|700px|Bentiromide synthesis:<ref>P. L. De Benneville, N. J. Greenberger, {{cite patent|DE|2156835}}; eidem, {{US patent|3801562}} (1972, 1974 both to Rohm & Haas).</ref> Synthesis, in vitro and in vivo data:<ref>{{cite journal|doi=10.1021/jm00281a002|pmid=4654657|title=New substrates for a pancreatic exocrine function test|journal=Journal of Medicinal Chemistry|volume=15|issue=11|pages=1098|year=1972|last1=Debenneville|first1=Peter L.|last2=Godfrey|first2=William J.|last3=Sims|first3=Homer J.|last4=Imondi|first4=Anthony R.}}</ref>]]
It is synthesized by amide formation between ethyl ''p''-aminobenzoate and ''N''-benzoyl-tyrosine using ''N''-methyl-morpholine and ethyl chlorocarbonate for activation. The resulting L-amide is selectively hydrolyzed by sequential use of [[dimsyl sodium]] ([[NaDMSO]]) and dilute acid to give bentiromide ('''4''').

== See also ==
* [[Chronic pancreatitis]]

== References ==
{{reflist}}

{{Diagnostic agents}}

[[Category:Benzoic acids]]


{{pharma-stub}}